RCMI Team

Olaleye, Omonike, Ph.D. MPH.
(Principal Investigator)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

Huan Xie, Ph.D, Ph.D. MPH.
(Principal Investigator)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

Dong Liang, Ph.D.
(Program Director)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

China Jenkins, PhD, APTD, CFD.
(TEAM Coordinator)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

Dong Liang, Ph.D.
(Program Director)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

Dong Liang, Ph.D.
(Program Director)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.

Mario Hollomon, Ph.D.
(Program Director)

Omonike is an Associate Professor of Pharmacology and Assistant Dean for Student Services in the College of Pharmacy and Health Sciences (COPHS) at Texas Southern University (TSU). She has over 15 years of research experience in drug discovery and development in major pharmaceutical companies (Merck Research Laboratories and Bristol Meyers Squibb) and academia. Her formal training in pharmacology was at the Johns Hopkins University School of Medicine (JHU), Baltimore, Maryland. At JHU, she was awarded prestigious pre-doctoral fellowships from both National Aeronautics Space Administration (NASA) and Merck Research Laboratories. Dr. Olaleye’s research efforts have been focused on the discovery and development of new therapeutic agents for treatment of infections caused by: Mycobacterium tuberculosis, Human Immunodeficiency Virus (HIV), Leishmania major, and Enterococcus faecalis. To date, she has discovered and characterized structurally diverse small molecule inhibitors with potent and selective activity against M. tuberculosis, E. faecalis and L. major.